Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 2
2017 2
2019 2
2021 1
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
Highly hypofractionated schedules for localized prostate cancer: Recommendations of the GETUG radiation oncology group.
Lapierre A, Hennequin C, Beneux A, Belhomme S, Benziane Ouaritini N, Biston MC, Crehange G, de Crevoisier R, Dumas JL, Fawzi M, Lisbona A, Pasquier D, Pelissier S, Graff-Cailleaud P, Pommier P, Sargos P, Simon JM, Supiot S, Tantot F, Chapet O. Lapierre A, et al. Among authors: tantot f. Crit Rev Oncol Hematol. 2022 May;173:103661. doi: 10.1016/j.critrevonc.2022.103661. Epub 2022 Mar 25. Crit Rev Oncol Hematol. 2022. PMID: 35341986 Review.
Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial.
Courcier J, Dalban C, Laguerre B, Ladoire S, Barthélémy P, Oudard S, Joly F, Gravis G, Chevreau C, Geoffrois L, Deluche É, Rolland F, Topart D, Culine S, Négrier S, Mahammedi H, Tantot F, Jamet A, Escudier B, Flippot R, Albigès L. Courcier J, et al. Among authors: tantot f. Eur Urol. 2021 Sep;80(3):325-329. doi: 10.1016/j.eururo.2021.05.020. Epub 2021 Jun 5. Eur Urol. 2021. PMID: 34103181 Clinical Trial.
Impact of Early Consumption of High-Fat Diet on the Mesolimbic Dopaminergic System.
Naneix F, Tantot F, Glangetas C, Kaufling J, Janthakhin Y, Boitard C, De Smedt-Peyrusse V, Pape JR, Vancassel S, Trifilieff P, Georges F, Coutureau E, Ferreira G. Naneix F, et al. Among authors: tantot f. eNeuro. 2017 Jun 1;4(3):ENEURO.0120-17.2017. doi: 10.1523/ENEURO.0120-17.2017. eCollection 2017 May-Jun. eNeuro. 2017. PMID: 28580417 Free PMC article.
Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Flippot R, Dalban C, Laguerre B, Borchiellini D, Gravis G, Négrier S, Chevreau C, Joly F, Geoffrois L, Ladoire S, Mahammedi H, Rolland F, Gross-Goupil M, Deluche E, Priou F, Laramas M, Barthélémy P, Narciso B, Houedé N, Culine S, Oudard S, Chenot M, Tantot F, Chabaud S, Escudier B, Albiges L. Flippot R, et al. Among authors: tantot f. J Clin Oncol. 2019 Aug 10;37(23):2008-2016. doi: 10.1200/JCO.18.02218. Epub 2019 Jun 13. J Clin Oncol. 2019. PMID: 31194611 Clinical Trial.
Efficacy and Safety of Concomitant Proton Pump Inhibitor and Nivolumab in Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study.
Rassy E, Dalban C, Colomba E, Derosa L, Alves Costa Silva C, Negrier S, Chevreau C, Gravis G, Oudard S, Laguerre B, Barthelemy P, Goupil MG, Geoffrois L, Rolland F, Thiery-Vuillemin A, Joly F, Ladoire S, Tantot F, Escudier B, Albiges L. Rassy E, et al. Among authors: tantot f. Clin Genitourin Cancer. 2022 Oct;20(5):488-494. doi: 10.1016/j.clgc.2022.07.003. Epub 2022 Jul 10. Clin Genitourin Cancer. 2022. PMID: 35977881 Clinical Trial.
Baseline circulating unswitched memory B cells and B-cell related soluble factors are associated with overall survival in patients with clear cell renal cell carcinoma treated with nivolumab within the NIVOREN GETUG-AFU 26 study.
Carril-Ajuria L, Desnoyer A, Meylan M, Dalban C, Naigeon M, Cassard L, Vano Y, Rioux-Leclercq N, Chouaib S, Beuselinck B, Chabaud S, Barros-Monteiro J, Bougoüin A, Lacroix G, Colina-Moreno I, Tantot F, Boselli L, De Oliveira C, Fridman WH, Escudier B, Sautes-Fridman C, Albiges L, Chaput-Gras N. Carril-Ajuria L, et al. Among authors: tantot f. J Immunother Cancer. 2022 May;10(5):e004885. doi: 10.1136/jitc-2022-004885. J Immunother Cancer. 2022. PMID: 35640928 Free PMC article. Clinical Trial.